Allena Pharmaceuticals, Inc. Shareholders Equity (Other)

Shareholders Equity (Other) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Shareholders Equity (Other) for the quarter ending June 30, 2017 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Other) decreased by NaN%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Other) of Allena Pharmaceuticals, Inc.

Most recent Shareholders Equity (Other)of ALNA including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Other) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Shareholders Equity (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2017 $0.0 $0.0
2016 $0.0
2015 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.